Maat

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Survival, Maat, Fatty acid, Patient, SCFA, Cancer, AACR, MET, Pharmaceutical industry

MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.

Key Points: 
  • MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.
  • The MET-C platform enables MaaT Pharma to produce microbiome therapies at a large-scale to meet the needs of larger market indications.
  • The data published represents significant advancements in understanding the mechanism of action (MoA) of co-cultured microbiome therapies developed by MaaT Pharma, marking a major step towards clinical evaluation.
  • These findings support the role of MaaT034 in gut barrier repair and in T cell reactivation either in combination with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1).

MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, AP-HP, Bone marrow, Survival, Immunotherapy, Patient, Innovation, IND, Ipilimumab, European Medicines Agency, Therapy, Artificial intelligence, Charcot disease, ASH, EMA, Head, MET, Investigational New Drug, Nivolumab, Safety, SITC, Microbiome, Food, ODD, Development, Acceleration, Maat, ARES, Cancer, AACR, DSMB, Haematopoietic system, Annual general meeting, OS, EUR, Physician, CIMON, CGMP, EAP, EBMT, ICI, Society, Randomized controlled trial, Symantec Endpoint Protection, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.
  • In December 2023 , the Company presented positive results from the Early Access Program (EAP) in Europe involving 111 patients with aGvHD treated with MaaT013, at the 2023 American Society of Hematology (ASH) Annual Meeting.
  • In April 2023 , data from the Phase 1b study (CIMON) with MaaT033, previously communicated during the 64th annual ASH meeting, were also presented at the EBMT 2023 conference.
  • During 2023 and Q1 2024, MaaT Pharma reinforced its board of directors, executive team, and key functions:
    Karim Dabbagh as Chairman and Nadia Kamal as Director, both independent.

MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neurology, Growth, Survival, Doctor of Pharmacy, Microbiota, Maat, Patient, Ipsen, Cancer, MET, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.
  • Jonathan Chriqui will be responsible for MaaT Pharma’s business development and partnering strategies along with promoting MaaT Pharma's innovations within the microbiome industry.
  • MaaT Pharma is now poised to propel its lead asset, MaaT013, into the next phase of development and prepare for its commercial launch,” said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma.
  • I look forward to contributing to the advancement of MaaT013 towards the market and supporting the company’s mission of providing new treatment options for patients with cancer,” shared Jonathan Chriqui, Chief Business Officer at MaaT Pharma.

MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

Retrieved on: 
Thursday, November 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ministry, Bone marrow, Apollo, Maat, CFO, Acceleration, Innovation, Patient, Multimedia, Bioproduction, Cancer, Survival, MET, Partnership, Pharmaceutical industry

“We're honored to receive this funding, contributing to France's leadership in innovative biotherapies.

Key Points: 
  • “We're honored to receive this funding, contributing to France's leadership in innovative biotherapies.
  • This is consistent with announcements from the French government in accelerating production of biomedicines in France.
  • MaaT Pharma’s MaaT033 program is an ambitious project aimed at using MaaT033 in a larger market in a chronic and ambulatory setting for patients receiving allo-HSCT2 during blood cancer treatment.
  • MaaT Pharma is set to receive €7.4 million in funding for a project totaling €16.4 million over a 23-month period.

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Bone marrow, Annual general meeting, Charcot disease, European Medicines Agency, Maat, ICI, HSCT, Randomized controlled trial, CFO, ASH, Artificial intelligence, EMA, Patient, DSMB, PICASSO, Medi-Cal Access Program, Aryl hydrocarbon receptor, Hematopoietic stem cell transplantation, Immunotherapy, EUR, Therapy, Symantec Endpoint Protection, ORR, Cancer, Survival, MET, SITC, ARES, CGMP, Development, Society, Pharmaceutical industry, Vaccine, ALS

We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.

Key Points: 
  • We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.
  • MaaT Pharma reported revenues from its compassionate access program of EUR 0.4 million for the quarter ended September 30, 2023 comparable with the third quarter of 2022.
  • 2 The Company would like to correct a clerical error that was present in its Q2 results press release of July 27, 2023.
  • The EUR 0.9 million figure was the difference in revenue between H1 2023 and H1 2022 (EUR 1.4 million vs. EUR 0.5 million).

MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Partnership, CIMON, ASH, ICI, DSMB, Head, European Medicines Agency, Survival, Charcot disease, Clinical trial, Cancer, SITC, Immunotherapy, Maat, EMA, Development, ARES, Investigational New Drug, PICASSO, Patient, CGMP, Microbiome, Lifting, MET, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, IND, Food, Pharmaceutical industry, Nursing, Rare-earth element, Management, HSCT, Alexis de Tocqueville, ALS

Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.

Key Points: 
  • Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.
  • In June 2023 , MaaT Pharma also announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced joining the Microbiome Therapeutics Innovation Group (MTIG).
  • The key unaudited financial results for the first half of 2023 are as follows:

MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

Retrieved on: 
Tuesday, September 12, 2023
Biotechnology, Pharmaceutical, Health, GMP, Partnership, Agility, Survival, Cancer, Multimedia, Maat, Development, CDMO, Patient, MET, Growth, Ecosystem, Environment, Pharmaceutical industry, Fine chemical

The companies had entered a partnership in February 2022 to build the largest cGMP1 facility, to date, for full ecosystem microbiome therapies in Europe.

Key Points: 
  • The companies had entered a partnership in February 2022 to build the largest cGMP1 facility, to date, for full ecosystem microbiome therapies in Europe.
  • This new GMP manufacturing facility is a testament to the continued growth of MaaT Pharma,” stated Hervé Affagard, CEO and co-founder of MaaT Pharma.
  • “The on-time completion of our first Skyehub facility is a major achievement for Skyepharma and our partner MaaT Pharma.
  • These therapies demand advanced manufacturing techniques and procedures and will contribute to the growth of the microbiome sector in France.

MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, EBMT, IPO, EAP, CIMON, Failure, ICI, ASH, DSMB, Head, Charcot disease, Survival, Cancer, AGM, Research, American Society of Hematology, Maat, EMA, EUR, ARES, Science, Investigational New Drug, PICASSO, Patient, European, Microbiome, MET, Knowledge, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, ORR, Food, Pharmaceutical industry, Management, Lists of plant diseases, ALS

"As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.

Key Points: 
  • "As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.
  • In June 2023 , MaaT Pharma announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced having joined the Microbiome Therapeutics Innovation Group (MTIG).
  • MaaT Pharma reported revenues2 from its compassionate access program of EUR 0.7 million for the quarter ended June 30, 2023, comparable with EUR 0.7 million for the first quarter of 2023.

MaaT Pharma Joins Microbiome Therapeutics Innovation Group

Retrieved on: 
Thursday, July 20, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Partnership, Genetic analysis, Therapy, Policy, Survival, Cancer, Human, Research, David Berry (inventor), Maat, Patient, Microbiome, MET, FDA, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that the Company is now a member of Microbiome Therapeutics Innovation Group (MTIG).

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that the Company is now a member of Microbiome Therapeutics Innovation Group (MTIG).
  • "We are pleased to welcome MaaT Pharma to our diverse coalition of microbiome-based companies.
  • We eagerly anticipate a productive and collaborative partnership with MTIG and its members to accelerate the transformation of fundamental research into market-ready microbiome innovations.”
    The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.
  • Today, MTIG is comprised of twelve microbiome therapeutics companies: Bacthera, BiomeSense, Bio-Me, Genetic Analysis, MaaT Pharma, Microba Life Sciences, Rebiotix, Inc., a Ferring Company, Seres Therapeutics, Servatus Biopharmaceuticals, Siolta Therapeutics, and Vedanta Biosciences.

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Retrieved on: 
Monday, April 24, 2023
Research, Hospitals, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Therapy, Survival, Cancer, Maat, ARES, Investigational New Drug, Patient, Agency, MET, Special access program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

“We are grateful for the FDA’s continued engagement and are very pleased with the lift of the hold on MaaT013’s IND application.

Key Points: 
  • “We are grateful for the FDA’s continued engagement and are very pleased with the lift of the hold on MaaT013’s IND application.
  • “Today’s positive answer is also an exciting moment for MaaT Pharma in its mission to help patients through safe and innovative medicines.
  • We are now in a position to start discussions with the FDA for the clinical evaluation of MaaT033, our second drug-candidate, in the U.S.,” added Mr. Affagard.
  • “This step forward for us will also contribute to progress across the microbiome field and confirms MaaT Pharma’s position as a leader in the industry.”